Compounds and methods for increasing neurogenesis

• US 20050209142A1
• Filed: 11/19/2004
• Published: 09/22/2005
• Est. Priority Date: 11/20/2002
• Status: Abandoned Application

• Current Assignee: NeuroNova AB (Newron Pharmaceuticals Spa)
• Original Assignee: NeuroNova AB (Newron Pharmaceuticals Spa)
• Inventors: Jansson, Katarina, Lindquist, Per, Mercer, Alex, Zachrisson, Olof, Wikstrom, Lilian, Bertilsson, Goran, Patrone, Cesare, Ronnholm, Harriet, Hellstrom, Nina, McGuire, Jacqueline, Heidrich, Jessica, Lundh, Hanna, Frisen, Jonas, Kortesmaa, Jarkko, Haegerstrand, Anders, Erlandsson, Rikard, Nyberg, Karl, Haggblad, Johan, Ossoinak, Amina
• Application Number:
  US10/993,667
• Publication Number:
  US 20050209142A1
• Time in Patent Office: Days
• US Class Current: 514/8.300
• CPC Class Codes: A61K 31/675 having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• CPC Class Codes: A61K 35/30 Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
• CPC Class Codes: A61K 38/2278 Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
• CPC Class Codes: A61K 38/23 Calcitonins
• CPC Class Codes: A61K 38/26 Glucagons

Abstract

The invention is directed to methods of promoting neurogenesis by contacting neuronal tissue with neurogenesis modulating agents. Novel methods for treating neurological disorders using neurogenesis modulating agents are disclosed.

Claims

1. A method for modulating neurogenesis in neural tissue of a patient exhibiting at least one symptom of a central nervous system disorder selected from the group consisting of neurodegenerative disorders, ischemic disorders, neurological traumas, and learning and memory disorders, comprising:

administrating at least one agent selected from the group consisting of Thyrocalcitonin, Calcitonin, Exendin, and functional analogs, variants and combinations thereof, wherein the agent modulates neurogenesis in the patient, thereby modulating neurogenesis in the neural tissue of the patient.

2. The method of claim 1 wherein said agent is a calcitonin analog selected from the group consisting of katacalcin, calcitonin-gene-related-peptide, calcitonin-receptor-stimulating-peptides 1, calcitonin-receptor-stimulating-peptides 2, calcitonin-receptor-stimulating-peptides 3, PHM-27, Intermedin, [Asp(17), Lys(21)] side-chain bridged salmon calcitonin, [Asp(17) Orn(21)] side-chain bridged salmon calcitonin, AC512, benzophenone-containing CT analogs, [Arg11, 18, Lys14] salmon calcitonin analog, eel calcitonin analog, calcitonin 8-32, and analogs and combinations thereof.

3. The method of claim 1 wherein said agent is an calcitonin family peptide member selected from the group consisting of CGRP 8-37, amylin amide, and analogs thereof.

4. The method of claim 1 wherein said Exendin is Exendin-3 or Exendin-4.

5. The method of claim 1 wherein said agent is an Exendin functional analog selected from the group consisting of GLP-1 peptide, GLP-1 analog, CJC-1131, liraglutide, pramlintide, AVE-0010, and alpha-me-GLP-1.

6. The method of claim 1 wherein said agent is an Exendin functional analog peptide with an amino acid sequence selected from the group consisting of SEQ ID No:

21, SEQ ID No;

27, SEQ ID No;

69, SEQ ID No;

70, SEQ ID No;

71, SEQ ID No;

72, SEQ ID No;

73, SEQ ID No;

74, SEQ ID No;

75, SEQ ID No;

76, SEQ ID No;

77, SEQ ID No;

78, SEQ ID No;

79, SEQ ID No;

80, and SEQ ID No;

81.

7. The method of claim 1 wherein the agent is a GLP-1 receptor ligand peptide or a PACAP receptor ligand peptide.

8. The method of claim 1 wherein the nervous system disorder is selected from the group consisting of Parkinson'"'"'s disease and Parkinsonian disorders, Huntington'"'"'s disease, Alzheimer'"'"'s disease, multiple sclerosis, amyotrophic lateral sclerosis, Shy-Drager syndrome, progressive supranuclear palsy, Lewy body disease, spinal ischemia, ischemic stroke, cerebral infarction, spinal cord injury, and cancer-related brain and spinal cord injury, multi-infarct dementia, geriatric dementia, cognition impairment, depression and traumatic injury.

9. The method of claim 1 wherein said modulating neurogenesis is performed by an activation of a GPCR receptor in said neural tissue.

10. The method of claim 1 wherein the agent is administered to achieve a tissue concentration of 0.0001 nM to 50 nM.

11. The method of claim 1 wherein the agent is administered at an amount selected from the group consisting of from about 0.5 microgram to about 100 micrograms per day, about 0.1 microgram to about 20 micrograms per day, about 0.2 microgram to about 40 micrograms per day, about 5 micrograms to about 200 micrograms per day, about 10 micrograms to about 20 micrograms per day, about 20 micrograms to about 200 micrograms per day, about 50 micrograms to about 100 mg per day, about 0.1 mg to about 200 mg per day, about 50 mg to about 200 mg per day, and about 0.1 to about 1 gram per day.

12. A method for modulating neurogenesis in vitro comprising the steps of:

a) culturing a population of neural cells comprising neural stem cells;

b) adding to the cultured cells at least one neurogenesis modulating agent;

c) repeating steps b until a desired level of neurogenesis in achieved.

13. A method for alleviating a symptom of a disease or disorder of the central nervous system in a patient comprising the steps of:

(a) providing a population of neural stem cells or neural progenitor cells;

(b) contacting the neural stem cells or neural progenitor cells with at least one neurogenesis modulating agent; and

(c) delivering the cells to a patient to alleviate the symptom.

14. The method of claim 13 further comprising the step of administering the at least one neurogenesis modulating agent to the patient for a period of time before the step of delivering the cells.

15. The method of claim 13 further comprising the step of administering the at least one neurogenesis modulating agent after said delivering step.

16. A method for transplanting a population of cells enriched for neural stem cells from a donor to a recipient comprising:

(a) contacting a population containing neural stem cells or neural progenitor cells derived from a donor with a neurogenesis modulating agent; and

(b) implanting the selected cells into a recipient.

17. The method of claim 16 wherein said contacting step comprises:

a) culturing a population of neural cells comprising neural stem cells from said donor;

b) adding to the cultured cells at least one neurogenesis modulating agent;

c) repeating steps b until a desired level of neurogenesis in achieved.

18. The method of claim 16 wherein said donor and recipient is the same organism.

19. A method for increasing adult neural stem cells in a patient with a disorder of the central nervous system comprising administering to said patient an amount of an Exendin or Exendin analog sufficient to increase adult neural stem cells in said patient and reduce at least one symptom of said disorder.

20. The method of claim 19, wherein said Exendin or Exendin analog a peptide with an amino acid sequence selected from the group consisting of SEQ ID No:

21, SEQ ID No;

27, SEQ ID No;

69, SEQ ID No;

70, SEQ ID No;

71, SEQ ID No;

72, SEQ ID No;

73, SEQ ID No;

74, SEQ ID No;

75, SEQ ID No;

76, SEQ ID No;

77, SEQ ID No;

78, SEQ ID No;

79, SEQ ID No;

80, and SEQ ID No;

81.

21. The method of claim 19 wherein said disorder is selected from the group consisting of Parkinson'"'"'s disease and Parkinsonian disorders, Huntington'"'"'s disease, Alzheimer'"'"'s disease, multiple sclerosis, amyotrophic lateral sclerosis, Shy-Drager syndrome, progressive supranuclear palsy, Lewy body disease, spinal ischemia, ischemic stroke, cerebral infarction, spinal cord injury, and cancer-related brain and spinal cord injury, multi-infarct dementia, geriatric dementia, cognition impairment, depression and traumatic injury.

22. The method of claim 19 wherein said Exendin or Exendin analog is administered at an amount of about 0.001 microgram to about 20 micrograms per kilogram of body weight per day.

23. The method of claim 19 wherein said Exendin or Exendin analog is administered at an amount of about 0.01 microgram to about 2 micrograms per kilogram of body weight per day.

24. The method of claim 19 wherein said Exendin or Exendin analog is administered at an amount of about 0.02 microgram to about 0.4 microgram per kilogram of body weight per day.